Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) EBIT Margin (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed EBIT Margin for 5 consecutive years, with 17336.03% as the latest value for Q4 2025.

  • Quarterly EBIT Margin changed N/A to 17336.03% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6110.71% through Dec 2025, changed N/A year-over-year, with the annual reading at 11654.75% for FY2023, 1034138.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 17336.03% at Pliant Therapeutics, up from 3468.59% in the prior quarter.
  • The five-year high for EBIT Margin was 17336.03% in Q4 2025, with the low at 19083.87% in Q2 2023.
  • Average EBIT Margin over 4 years is 42.05%, with a median of 1255.42% recorded in 2021.
  • The sharpest move saw EBIT Margin skyrocketed 68612bps in 2022, then tumbled -1848972bps in 2023.
  • Over 4 years, EBIT Margin stood at 1230.57% in 2021, then plummeted by -55bps to 1903.31% in 2022, then tumbled by -903bps to 19083.87% in 2023, then soared by 191bps to 17336.03% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 17336.03%, 3468.59%, and 5635.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.